Working… Menu
Trial record 77 of 317 for:    colon cancer | ( Map: Canada )

Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00030563
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : April 17, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Raymond Yeung, University of Washington

Brief Summary:

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug after surgery and radiofrequency ablation may kill any remaining tumor cells.

PURPOSE: Phase II trial to determine the effectiveness of surgery with or without radiofrequency ablation followed by irinotecan in treating patients who have colorectal cancer that is metastatic to the liver.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Metastatic Cancer Drug: irinotecan hydrochloride Procedure: adjuvant therapy Procedure: conventional surgery Procedure: radiofrequency ablation Phase 2

Detailed Description:


  • Determine the disease-free survival in patients with hepatic metastases from primary colorectal carcinoma treated with surgical resection with or without radiofrequency ablation followed by irinotecan.
  • Determine the overall survival in patients treated with this regimen.
  • Determine the treatment-related toxicity of this regimen in these patients.
  • Correlate the measurement of molecular markers with clinical outcome in patients treated with this regimen.

OUTLINE: This is a multicenter study. Patients are stratified according to treatment with radiofrequency ablation in addition to resection (yes vs no).

Patients undergo surgical resection with or without radiofrequency ablation. Beginning 4-8 weeks after surgery, patients receive irinotecan IV over 90 minutes on day 1. Chemotherapy repeats every 3 weeks for a total of 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed at 4 weeks, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: A Phase II Study Of Adjuvant Intravenous Irinotecan Following Resection With Or Without Radiofrequency Ablation (RFA), Of Hepatic Metastases From Colorectal Carcinoma
Study Start Date : May 2001
Actual Primary Completion Date : October 2004
Actual Study Completion Date : October 2005

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed primary colorectal adenocarcinoma
  • Hepatic metastases that are considered completely resectable

    • No more than 4 metastases by dual phase CT scan OR
  • Hepatic metastases that are not completely resectable but are amenable to complete destruction with resection and radiofrequency ablation

    • More than 4 metastases allowed if all disease can be resected or destroyed in situ with radiofrequency ablation
  • No extrahepatic disease in any location
  • No recurrent or second primary colorectal cancer by colonoscopy within the past year
  • Received prior adjuvant chemotherapy with a fluorouracil-based regimen with the last dose at least 1 month prior to surgery
  • No prior radiofrequency ablation with residual viable intrahepatic disease by CT scan
  • No plans to be treated with radiofrequency ablation alone without surgical resection



  • 18 and over

Performance status:

  • ECOG 0-1

Life expectancy:

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST and ALT no greater than 5 times ULN
  • No Gilbert's disease or other known defect in hepatic conjugation or glucuronidation


  • Creatinine no greater than 1.5 times ULN


  • No myocardial infarction within the past 6 months
  • No congestive heart failure requiring therapy


  • Not pregnant or nursing
  • Fertile patients must use effective contraception during and for 30 days after study
  • No other malignancy within the past 5 years except inactive non-melanoma skin cancer or carcinoma in situ of the cervix
  • No active serious infection
  • No other serious underlying medical condition or severe concurrent disease that would preclude study participation
  • No dementia, significantly altered mental status, or psychiatric illness that would preclude study participation
  • No known hypersensitivity to irinotecan
  • No known infection with HIV or AIDS
  • No uncontrolled diabetes mellitus
  • No history of seizures
  • No drug or alcohol abuse within the past year


Biologic therapy:

  • Not specified


  • See Disease Characteristics
  • No prior irinotecan

Endocrine therapy:

  • Not specified


  • No prior radiotherapy to more than 30% of bone marrow
  • No prior radiotherapy to the liver
  • At least 3 months since prior radiotherapy to the pelvis or other areas


  • See Disease Characteristics
  • No prior resection of hepatic metastases (wedge biopsy allowed)


  • No concurrent phenytoin, phenobarbital, or other antiepileptic medication
  • No concurrent enrollment in other investigational drug trials

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00030563

Layout table for location information
United States, Ohio
Ireland Cancer Center
Cleveland, Ohio, United States, 44106-5065
United States, Washington
University of Washington School of Medicine
Seattle, Washington, United States, 98195
Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
University of Washington
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Kevin G. Billingsley, MD University of Washington

Layout table for additonal information
Responsible Party: Raymond Yeung, Professor, Division of General Surgery, Oncology, University of Washington Identifier: NCT00030563     History of Changes
Other Study ID Numbers: 18033
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: April 17, 2017
Last Verified: April 2017
Keywords provided by Raymond Yeung, University of Washington:
liver metastases
stage IV colon cancer
stage IV rectal cancer
adenocarcinoma of the colon
adenocarcinoma of the rectum
recurrent colon cancer
recurrent rectal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents